Through the heart and beyond: a review on ranolazine

Monaldi Arch Chest Dis. 2021 Sep 9;92(1). doi: 10.4081/monaldi.2021.1806.

Abstract

Ranolazine derives from piperazine and has been approved as a drug for the therapy of chronic stable angina. It acts by selectively inhibiting the late sodium inward current. Moreover, ranolazine has other metabolic features which makes it effective in other diseases as well as coronary artery ones. In this paper I make an updated review of all possible therapeutic roles of ranolazine: through cardiology and beyond.

Publication types

  • Review

MeSH terms

  • Acetanilides* / therapeutic use
  • Heart
  • Humans
  • Piperazines* / pharmacology
  • Piperazines* / therapeutic use
  • Ranolazine / therapeutic use

Substances

  • Acetanilides
  • Piperazines
  • Ranolazine